Trial of a preferential Phosphodiesterase 4B Inhibitor for idiopathic pulmonary fibrosis.
16 May, 2022 | 02:32h | UTCTrial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
https://twitter.com/NEJM/status/1525878684380430343